Subcontracting Opportunities
Subcontracting allows small and disadvantaged businesses to substantially impact the federal procurement preference programs. Due to legislative mandates, federal prime contractors award billions of subcontracting dollars annually to small businesses — Small Business Subcontracting Plan requirements set forth in their contracts include requirements to track participation by veteran-owned, service-disabled veteran-owned, HUBZone, disadvantaged, and women-owned businesses.
USASpending.gov provides information on organizations who have a prime contractor relationship with the NCI. The current Frederick National Laboratory for Cancer Research (FNLCR) prime contractor has significant subcontracting opportunities — see FNLCR Acquisitions for further information.
NCI also maintains a list of its active Indefinite Delivery/Indefinite Quantity (ID/IQ) Prime Contractors. NCI encourages businesses to network and establish teaming arrangements to support these contracting vehicles, which are used to place a variety of orders for supplies and services through processes that do not involve public posting after the base ID/IQ contract(s) have been awarded.
| Contract # | Contractor Name(s) | Title & Brief Description From Article B.1. | Base Period of Performance (Start-End Dates) |
|---|---|---|---|
| HHSN261201300008I | Information Management Services, Inc. | Computing Services for the Division of Cancer Prevention, NCI - provides programming and data management services including project management, data management, computer programming, computing infrastructure services, website development and systems design and development. | 05/10/2013 - 05/09/2020 |
| HHSN261201400002I | Technical Resources, Inc | Cancer Prevention Clinical Trials Auditing and Informatics Support | 05/30/2014 - 05/29/2019 |
| HHSN261201400004I | North American Association of Central Cancer Registries (NAACCR) | The objective of this contract is provide support to the North American Association of Central Cancer Registries (NMCCR) in order to make the National Cancer lnstitute's (NCI) cancer surveillance program more responsive to the needs of the division, institute, and nation, and more integrated with other partners within the national cancer surveillance enterprise.This contract focuses on three specific areas: (1) Strengthening the national capacity for collecting, analyzing, and using comparable cancer registry data for cancer surveillance and research. (2) Developing and improving methods for assessing the quality and comparability of cancer registry data. This includes, but is not limited to timeliness, completeness, and accuracy. (3) Improving the efficiency and quality of registry operationsthrough promoting established standards, disseminating technical information, and facilitating collaboration among Federal, state, provincial and local registry professionals. |
07/01/2014 - 06/30/2021 |
| HHSN261201400005I | Vignet | (NMCCR) in order to make the National Cancer lnstitute's (NCI) cancer surveillance program more responsive to the needs of the division, institute, and nation, and more integrated with other partners within the national cancer surveillance enterprise.This contract focuses on three specific areas: (1) Strengthening the national capacity for collecting, analyzing, and using comparable cancer registry data for cancer surveillance and research. (2) Developing and improving methods for assessing the quality and comparability of cancer registry data. This includes, but is not limited to timeliness, completeness, and accuracy. (3) Improving the efficiency and quality of registry operations through promoting established standards, disseminating technical information, and facilitating collaboration among Federal, state, provincial and local registry professionals. | 09/12/2014 - 09/11/2021 |
| HHSN261201400006I | CDM Group | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 09/12/2014 - 09/11/2021 |
| HHSN261201400007I | Gunnison | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 09/12/2014 - 09/11/2021 |
| HHSN261201400008I | Vsolvit | Technical Services for the NCI Applied Research Program - This contract provides a broad range of developmental and technical services related to cancer-associated health behaviors, health services and outcomes for cancer treatment. The services include study management, questionnaire development, and database development and management. | 09/12/2014 - 09/11/2021 |
| HHSN261201600007I | Westat, Inc | The Contractor shall provide support for centralized follow-up of participants from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening and the National Lung Screening (NLST) Trials. The PLCO was designed to determine if screening for prostate, lung, colorectal and ovarian cancer can reduce mortality from these cancers. The National Lung Screening Trial (NLST) was a randomized controlled trial designed to determine whether screening for lung cancer with low-dose helical computed tomography (CT) reduces mortality from lung cancer in high-risk individuals relative to screening with chest radiography. | 03/01/2016 - 02/28/2021 |
| HHSN261201700004I | Bizzell Group | Tobacco Control Research Scientific and Technical Services Support | 09/01/2017 - 08/31/2022 |
| HHSN261201700015I | Nationwide Children's Hospital | Biospcimen Core Resource (BCR) | 08/25/2017 - 08/24/2022 |
| HHSN26120180002I | Connecticut Department of Public Health | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800003I | Emory University | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800004I | Fred Hutchinson Cancer Research Center | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800005I | Health Research, Inc. | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800006I | Idaho Hospital Association | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800007I | Louisiana State University | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800008I | Massachusetts Department of Public Health | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800009I | Public Health Institute | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800010I | Cancer Prevention Institute of California (CPIC) | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800011I | University of Hawaii | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800012I | University of Iowa | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800013I | University of Kentucky (Research Foundation) | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800014I | University of New Mexico | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800015I | University of Southern California | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800016I | University of Utah | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800017I | Wisconsin Department of Health Services | Surveillance, Epidemiology and End Results (SEER) Program - collects and reports on population based cancer incidence and survival data on all patients in the legally described catchment area. | 05/1/2018 - 04/30/2028 |
| HHSN261201800031I | UCSF | The Contractor shall collect population-based cancer data and report on population-based cancer incidence, treatment, and survival data on all patients in the legally described geographic coverage area. The Contractor shall participate in cancer surveillance research efforts supported under the Statement of Work. These may include activities such as the Virtual Tissue Repository, Virtual Pooled Registry, Patterns of Care Studies, and other ancillary studies. |
05/1/2018 - 04/30/2028 |
| HHSN2612013000028I | Westat | To provide administrative, regulatory, logistical, and information technology support for the Cancer Trials Support Unit (CTSU) to gain operational efficiency for both CTSU and NCTN/MCOs, enhance proficiency, and deliver measurable business value. The Contractor shall build and maintain the operational infrastructure of the CTSU as described within the Statement of Work (SOW). | 08/31/2013 - 08/30/2020 |
| HHSN261201300029I | PPD | To provide administrative, regulatory, logistical, and information technology support for the Cancer Trials Support Unit (CTSU) to gain operational efficiency for both CTSU and NCTN/MCOs, enhance proficiency, and deliver measurable business value. The Contractor shall build and maintain the operational infrastructure of the CTSU as described within the Statement of Work (SOW). | 08/31/2013 - 08/30/2020 |
| HHSN261201400010I | Social and Scientific Systems, Inc | This contract is for support of the Radiation Epidemiology Branch for all phases of epidemiologic studies including initiation of pilot and full-scale field studies, coordination of multi-center studies, arranging for cooperation between NCI and its collaborators, support for study data collection, data acquisition and cleaning, and collection of biological specimens in the US and abroad. It is anticipated that the Contractor will need to provide support to 8-30 studies annually. | 08/31/2014 - 09/29/2019 |
| HHSN261201700003I | American Type Culture Collection | The Contractor shall provide Molecular Epidemiology Assay Support (MEAS) to the Division of Cancer Epidemiology and Genectics. | 05/06/2017 - 03/05/2022 |
| HHSN261201800020I | Henry Ford Health System | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 06/04/2018 - 06/03/2028 |
| HHSN261201800021I | Kaiser Foundation Hospitals | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 06/04/2018 - 06/03/2028 |
| HHSN261201800022I | Sanford Research | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 06/04/2018 - 06/03/2028 |
| HHSN261201800023I | The University of Chicago | The Contractor shall recruit and retain participants, collect and process biospecimens, administer online questionnaires, and link to electronic medical records in support DCEG's NextGeneration Cohort | 06/04/2018 - 06/03/2028 |
| HHSN261201700009I | Metabolon, Inc. | The Contractor shall provide metabolomic profiling services for DCEG studies using liquid chromatography and gas chromatography mass spectrometry (LC-MS). | 06/14/2017 - 06/13/2022 |
| HHSN261201700012I | Fundacion INCIENSA | Evaluation of Single Dose Protection Afforded by the Prophylactic HPV vaccines | 08/01/2017 - 07/31/2023 |
| HHSN261201800033I | Medidata Solutions | Rave Hosting, Maintenance, and Professional Services, and License, Hosting, Maintenance, and Professional Services for Rave integrated anicillary services. | 09/01/2018 - 08/31/2023 |
| HHSN261201500003I | Leidos Biomedical Research | OTS Contractor maintains flexibility and is rapidly responsive in supporting the evolving on-going research, emerging technologies and new research initiatives of the Government. Moreover, it is vital that the requirements of the Government be addressed proactively and that creativity and innovation be used in the performance of all aspects of this Statement of Work. | 09/14/2015 - 08/30/2019 |
| HHSN261201600015I | IITRI | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 07/01/2016 - 06/30/2021 |
| HHSN261201600016I | Battelle | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 07/01/2016 - 06/30/2022 |
| HHSN261201600017I | SRI | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 07/01/2016 - 06/30/2023 |
| HHSN261201600018I | Southern | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 07/01/2016 - 06/30/2024 |
| HHSN261201600019I | UIC | Preclinical Toxicology Study of Drugs Developed for Cancer and Other Diseases | 07/01/2016 - 06/30/2025 |
| HHSN261201800036I | Synergy | NCI Center for Global Health, Logistics, Data Analysis and Technical Support | 09/17/2018 - 09/16/2023 |
| HHSN261201700007I | Alchem | Synthesis of Non-GMP Small Molecules | 09/18/2017 - 09/17/2022 |
| HHSN261201600002I | 22nd Century Technologies Inc. | SharePoint Maintenance & Support Services (NCCIH & NCI) | 10/17/2015 - 10/16/2020 |
| 75N91019D00012 | IIT Research Institute | PREVENT Preclinical Drug Development Program (Efficacy Pool) | 01/25/2019 - 01/24/2024 |
| 75N91019D00014 | SRI International | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00016 | Illinois Univ, TRL | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00021 | University of Texas, MD Anderson | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00022 | The Research Institute of Fox Chase Cancer Center | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00013 | IIT Research Institute | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 01/25/2019 - 01/24/2024 |
| 75N91019D00018 | Southern Research Institute | PREVENT Preclinical Drug Development Program (Toxicology Pool) | 01/25/2019 - 01/24/2024 |
| 75N91019D00017 | Illinois Univ, TRL | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00019 | University of Alabama at Birmingham | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| 75N91019D00020 | University of Oklahoma Health Sciences Center | PREVENT Efficacy studies | 01/25/2019 - 01/24/2024 |
| HHSN261201500002B | Information Management Services (IMS) | The purpose of this acquisition is to provide computer systems analysis, programming, data management and maintenance, data analysis, statistical reporting, and documentation services for research efforts conducted by the National Cancer Institute (NCI). Tasks associated with this work include statistical programming and analytic consultation; systems analysis, design, programming, testing documentation maintenance support for computer systems; management, data entry, editing, file management, documentation, and program maintenance support for NCI databases; and computer system administration and resources to support analytic processing, client/server applications, web server applications, and file transfer options in a secure, firewall-protected environment. | 08/1/2015 - 07/27/2020 |
| HHSN261201600006I | Fisher BioServices Inc | NCI is seeking support services to operate and maintain the National Cancer Institute's Chemotherapeutic Agents Repository (NCI-CAR). The principal goals of this contract are 1) to support compound acquisition activities related to the DTP anticancer pre-clinical drug evaluation program which seeks to identify new small molecule therapeutic agents and 2) distribution of chemicals to intramural and extramural investigators for research purposes. The primary tasks of the contract are the receipt, registration, storage, analysis, arraying and distribution of small molecules and purified natural products. This contract is also responsible for providing an informational interface with NCI and external investigators that are submitting or requesting research compounds; for updating of the chemical database which includes chemical, inventory, receiving and shipping information; systematic file and record keeping of both current and archival information related to Repository activities; and reacquisition of samples for continued chemical and biological studies. | 03/1/2016 - 02/28/2021 |
| HHSN261201600020I | SRI International | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 07/01/2016 - 06/30/2021 |
| HHSN261201600021I | Southern Research | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 07/01/2016 - 06/30/2021 |
| HHSN261201600022I | University of Pittsburgh | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 07/01/2016 - 06/30/2021 |
| HHSN261201600023I | IITRI | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 07/01/2016 - 06/30/2021 |
| HHSN261201600024I | Mayo Clinic | The pupose of this acquisition is to continue implementation of bioanalytical methods and to conduct pharmacokinetic evaluations in aniamls with compounds of interest to the NCI Therapeutics (NeXT) Program. | 07/01/2016 - 06/30/2021 |
| HHSN261201500034I | ASTERAND US ACQUISITION CORP | Tissue source site for CPTAC Program | 09/22/2015 - 09/21/2020 |
| HHSN261201500046I | BIOMATRIX | Tissue source site for CPTAC Program | 09/29/2015 - 09/28/2020 |
| HHSN261201500047I | GLOBAL BIOCLINICAL | Tissue source site for CPTAC Program | 09/29/2015 - 09/28/2020 |
| HHSN261201600003I | INTERNATIONAL GENOMICS CONSORTIUM | Tissue source site for CPTAC Program | 01/15/2016 - 01/14/2021 |
| HHSN261201600004I | ANALYTICAL BIOLOGICAL SERVICES | Tissue source site for CPTAC Program | 01/19/2016 - 01/18/2021 |
| HHSN261201600005I | IIMO (POLAND) | Tissue source site for CPTAC Program | 12/30/2015 - 12/29/2020 |
| HHSN261201600008I | CEDARS-SINAI MEDICAL CENTER | Tissue source site for CPTAC Program | 03/2/2016 - 03/1/2021 |
| HHSN261201600009I | BEAUMONT HEALTH | Tissue source site for CPTAC Program | 02/24/2016 - 02/23/2021 |
| HHSN261201600010I | U. OF CALIFORNIA SAN DIEGO | Tissue source site for CPTAC Program | 03/23/2016 - 03/22/2021 |
| HHSN261201600011I | BOSTON MEDICAL CENTER | Tissue source site for CPTAC Program | 02/24/2016 - 02/23/2021 |
| HHSN261201600012I | BIOPARTNERS | Tissue source site for CPTAC Program | 02/24/2016 - 02/23/2021 |
| HHSN261201600026I | Centeva, LLC | Information Technology Systems & Support for NCI OA | 09/29/2016 - 09/28/2019 |
| HHSN261201700011I | MRIGlobal | Analysis of bulk drug samples and their pharmaceutical formulations |
08/1/2017 - 07/31/2022 |
| HHSN261201700013I | RTI International | Analysis of bulk drug samples and their pharmaceutical formulations |
08/1/2017 - 07/31/2022 |
| HHSN261201700014I | SRI International | Analysis of bulk drug samples and their pharmaceutical formulations |
08/1/2017 - 07/31/2022 |
| HHSN261201500009I | IriSys, LLC | Discovery and development of new therapeutic agents for treatment of cancer | 06/30/2015 - 06/29/2020 |
| HHSN261201500010I | Evotec (US), Inc. | Store and maintain the CBCSLC approximately 135,000 small molecule screening collections | 09/30/2015 - 09/29/2020 |
| HHSN261201500005I | The Hospital for Sick Children | Laboratory Testing Services of Serum Enzymes for Patients at Risk of Shwachman-Diamond Syndrome | 04/15/2015 - 04/14/2020 |
| HHSN261201500007I | Oregon Health & Science University | Laboratory Testing Services of Chromosome Breakage Analyses for the Inherited Bone Marrow Failure Study |
05/20/2015 - 05/19/2020 |
| HHSN261201500044I | Datawaves | Technology Transfer Center TIMS database Maintenance and Upgrades | 09/20/2015 (eff. Date 09/24/2015) - 09/19/2020 |
| HHSN261201500045I | Repeat Diagnostics, Inc. | Laboratory Testing Services of Telomere Length Assays for the Inherited Bone Marrow Failure Study | 09/20/2015 (eff. Date 09/22/2015) - 09/19/2020 |
| HHSN261201400020I | Centeva, LLC | Services for support of the National Cancer Institutes Office of Acquisitions (NCI OA) Information Technology Systems |
09/29/2014 - 09/28/2019 |
| HHSN261201700019I | Bayer Healthcare LLC | BPX30 Disposable Endorectal Coils for 3.OT MRI Scanner | 09/10/2017 - 09/17/2022 |
| HHSN261201500012I | Bayer Healthcare | Procurement of Coil, Disposable Endorectal 3.0T | 07/15/2015 - 07/14/2020 |
| HHSN261201500017I | Universite Laval | Services to determine serum concentrations of samples collected by the Hormonal and Reproductive Epidemiology Branch (HREB). |
09/01/2015 - 08/31/2020 |
| HHSN261201500033I | Artificial Intelligence in Medicine | Surveillance Epidemiology and End Results (SEER) Electronic Data Capture Software Support and Installations | 09/26/2015 - 09/25/2020 |
| HHSN261201400019I | Clontech Laboratories, Inc. | GMP Grade Retronectin | 09/30/2014 - 09/21/2019 |
| HHSN261201500016I | Gene Dx | Clinical Genetic Testing for TP53 | 08/10/2015 - 08/9/2020 |
| HHSN261201400012I | Asclepius Solutions | NCI Budget Management System (BMS); Content Mangement System (CMS); and Referral Connect Services and Support | 08/26/2014 - 08/25/2019 |
| HHSN261201400011I | Scientific Consulting Group | Applied Research Program (ARP) Meeting and Working Group Support | 8/15/2014 - 08/14/2019 |
| HHSN261201700003B | ICF Incorporated, LLC | Communication Services for NCI/DCCPS | 09/22/2017 - 09/29/2022 |
| HHSN261201700018I | PR Strategists LLC | Stratefic Workforce Planning and Executive Coaching | 09/08/2017 - 09/10/2022 |
| HHSN261201700017I | Genepria Consulting Inc. | Statistical and Programming Appplications | 09/12/2017 - 09/11/2022 |
| HHSN 261201700010I | Roche Diagnostics Corporation | BenchMark Ultra Reagents and Consumables | 06/22/2017 - 06/21/2019 |
| HHSN261201700006I | Leland Standord Junior Univerisity | Laboratory Services for HDV Antibody (anti0HDV), RNA and genotype testing | 04/03/2017 - 04/02/2020 |
| HHSN261201800019I | Olink Proteonimes | Testing Samples Using Inflammation and Cardiometabolic Panels | 05/01/2018 - 04/30/2020 |
| HHSN261201800025I | Becton, Dickinson and Company | Reagent, rental equipment, product supply, and maintenance for equipment in the Laboratory of Pathology | 06/28/2018 - 06/27/2018 |
| HHSN261201400019I | TAKARA BIO USA, INC. | GMP grade RetroNectin | 09/30/2014 - 09/29/2019 |
| HHSN261201600025I | Ganges, Mary Bruce Biological Research Consultant | Tissue Culture technician support p to 9000 hours with a minimum of 1400 hours | 08/20/2016 - 08/19/2021 |
| HHSN261201600027I | Vanderbilt University Medical Center | Laboratory Testing Services for Circulating Inflammation Markers and Prospective Risk of Gastric Cancer Related to the H Pylor | 09/14/2016 - 09/13/2021 |
| HHSN261201600030I | Invitae Corporation | Lab Testing/Dicer I Genetic Testing | 09/19/2016 - 09/21/2021 |
| HHSN261201800034I | D's Ventures LLC | Procurement of Gardasil-9 Vaccines in support of NCI/CCR | 9/18/2018 - 9/18/2021 |